Is It Time for (Survivorship Care) Plan B?
2011; Lippincott Williams & Wilkins; Volume: 29; Issue: 36 Linguagem: Inglês
10.1200/jco.2011.38.8397
ISSN1527-7755
AutoresThomas J. Smith, Claire Snyder,
Tópico(s)Health Systems, Economic Evaluations, Quality of Life
Resumobetween docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9:900-905, 2003 15. Hirth J, Watkins PB, Strawderman M, et al: The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:12551258, 2000 16. Hertz DL, Dees EC, Motsinger-Reif AA, et al: Breast cancer patients carrying the CYP2C8*3 variant are more likely to achieve clinical complete response from neoadjuvant paclitaxel treatment. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr PD07-10) 17. Berry DA: Adaptive clinical trials: The promise and the caution. J Clin Oncol 29:606-609, 2011 18. Woodcock J, Griffin JP, Behrman RE: Development of novel combination therapies. N Engl J Med 364:985-987, 2011
Referência(s)